Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

Launched by FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL CLÍNICO DE VALENCIA · Aug 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a new imaging technology called 3D-PANC MSP is better than traditional CT scans at evaluating how well treatment is working in patients with pancreatic cancer. Specifically, it focuses on patients who have a type of pancreatic cancer that is considered borderline or locally advanced. These patients will be receiving chemotherapy before surgery to remove the tumor. The researchers will compare the images from both the CT scans and the 3D technology against the actual results from the surgery and lab tests to see which method provides more accurate information.

To be eligible for this trial, patients must be diagnosed with borderline or locally advanced pancreatic cancer and must have received neoadjuvant (preoperative) treatment before they undergo surgery. However, patients under 18 years old, those who have had disease progression during treatment, or those who refuse to participate will not be included. Participants can expect to have their imaging assessed through both techniques, and the findings will help improve future approaches to treatment assessment. This study is currently recruiting participants and aims to gather valuable data over the next year.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas, as defined by the National Comprehensive Cancer Network (NCCN), who have received neoadjuvant treatment and who undergo surgical exploration with resective intent.
• Exclusion Criteria:
• • Patients younger than 18 years of age.
• • Patients under 18 years of age.
• • Disease progression during neoadjuvant treatment.
• • No preoperative CT scan.
• • Refusal to participate in the study.